What is CNSP's market cap?

$6.65M, based on the Nov 3 close of $4.55.

Does CNS Pharmaceuticals pay a dividend?

No regular cash dividend has been paid in the last year.

How much of CNSP is sold short?

1.3K shares, 0.1% of float, as of Oct 15, 2026.

What sector is CNSP in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · CNSPHealthcarePharmaceuticals

CNS Pharmaceuticals, Inc. Common Stock (CNSP)

$4.55+3.64%

Close Nov 3, 2026 · split-adjusted

Oct 30, 2026$5.00▼ 35.06% in range

Oct 31, 2025Low $2.13 · High $7.84Oct 30, 2026

What changed · written from our data

As of Nov 3, 2026

CNS Pharmaceuticals closed at $4.55 on Nov 3, up 3.64%, 42.0% below its 52-week closing high. Volume of 13.9K shares was 0.83× its 20-day average (close to normal).

Split-adjusted performance: -14.2% over one month, -36.4% over six months.

Short interest was 1.3K shares at the Oct 15 settlement, up 44.8% from the prior report (0.1% of float, 1.0 days to cover).

Market cap$6.6M1.5M shares

Revenue · quarter$0.00—

Diluted EPS$-0.38—

P/E · TTM—

Net margin—

Dividend yieldNone

52-week range2.13 – 7.84−42.0% from high

Volume13.9K0.83× 20-day avg

Volatility · 60d73.6%Annualised

Short % of float0.1%1.0 days to cover

Net cash$20.0MCash $20.0M

Next earnings—Not scheduled

Split-adjusted performance

1W −10.4%1M −14.2%3M −15.7%6M −36.4%YTD −13.3%1Y —3Y −100.0%5Y −100.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum36

Revenue growth—

Net margin—

Value (low P/E)—

Size10

Industry medians: 6-month return −26.5%, revenue growth +6.4%, net margin −38.1%, P/E 16.4×.

Short interest

Details →

Shares short1.3K+44.8% vs prior

Days to cover1.0Settled Oct 15

% of float0.1%

Short vol. 10d44.7%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
CNSPCNS Pharmaceuticals	$4.55	+3.64%	−36.4%	—	—	—	$6.6M
NAIINatural Alternatives International	$1.06	−0.93%	−59.4%	+1.9%	−39.2%	—	$6.6M	Compare
XCURExicure	$1.01	−0.98%	−70.3%	—	—	—	$6.6M	Compare
ENVBEnveric Biosciences	$1.50	+3.45%	−56.9%	—	—	—	$6.7M	Compare
APREAprea Therapeutics	$0.5150	+4.89%	−38.9%	−100.0%	—	—	$6.5M	Compare
FBLGFibroBiologics	$0.9900	+7.60%	−25.6%	—	—	—	$7.0M	Compare
ALZNAlzamend Neuro	$1.46	+16.80%	+36.4%	—	—	—	$7.0M	Compare
ENSCEnsysce Biosciences	$0.3777	−1.15%	−5.6%	−15.1%	−220.8%	—	$7.3M	Compare
VTGNVistagen Therapeutics	$0.1680	+0.30%	−72.0%	+504.9%	−882.8%	—	$7.5M	Compare

News about CNS Pharmaceuticals

All news →

No recent articles focused on CNS Pharmaceuticals. 1 articles mention it in passing.

Quick answers

What does CNS Pharmaceuticals do?: CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications.
What is CNSP's market cap?: $6.65M, based on the Nov 3 close of $4.55.
Does CNS Pharmaceuticals pay a dividend?: No regular cash dividend has been paid in the last year.
How much of CNSP is sold short?: 1.3K shares, 0.1% of float, as of Oct 15, 2026.
What sector is CNSP in?: Healthcare, in the Pharmaceuticals industry.

About CNS Pharmaceuticals

CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.

HQ: Houston, TX8 employeesListed Nov 8, 2019cnspharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology